Testing of Novel Treatment Options for Niemann-Pick Disease

Identification of Brain-Specific Treatment Effects in NPC1 Disease by Focusing on Cellular and Molecular Changes of Sphingosine-1-Phosphate Metabolism

The search for causative treatments continues to be a leading challenge in rare disease research. Using varying models, researchers recently investigated the potential effects of a novel candidate drug for improving neurological symptoms of Niemann-Pick disease. The study, which was coauthored by CENTOGENE’s CEO Prof. Arndt Rolfs, was published in the International Journal of Molecular Sciences.


  • Anne Gläser
  • et al.